{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:11:16Z","timestamp":1777677076867,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40265-015-0470-2","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T11:06:42Z","timestamp":1441969602000},"page":"1773-1781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Ruxolitinib: A Review in Polycythaemia Vera"],"prefix":"10.1007","volume":"75","author":[{"given":"Kate","family":"McKeage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,11]]},"reference":[{"issue":"1","key":"470_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1586\/17474086.2015.972359","volume":"8","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Komrokji RS. Novel and emerging therapies for the treatment of polycythemia vera. Expert Rev Hematol. 2015;8(1):101\u201313.","journal-title":"Expert Rev Hematol."},{"issue":"24","key":"470_CR2","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","volume":"124","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124(24):3529\u201337.","journal-title":"Blood."},{"key":"470_CR3","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176\u201384.","journal-title":"Blood."},{"key":"470_CR4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.blre.2014.12.002","volume":"29","author":"MH Kroll","year":"2015","unstructured":"Kroll MH, Michaelis LC, Verstovsek S. Mechanisms of thrombogenesis in polycythemia vera. Blood Rev. 2015;29:215\u201321.","journal-title":"Blood Rev."},{"key":"470_CR5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood."},{"key":"470_CR6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A. CME information: polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management. Am J Hematol. 2015;90:162\u201373.","journal-title":"Am J Hematol."},{"key":"470_CR7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","volume":"126","author":"T Barbui","year":"2015","unstructured":"Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126:560\u20131.","journal-title":"Blood."},{"key":"470_CR8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","volume":"55","author":"J Mehta","year":"2014","unstructured":"Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55:595\u2013600.","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"470_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2012-02-366054","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F. How I treat polycythemia vera. Blood. 2012;120(2):275\u201384.","journal-title":"Blood."},{"key":"470_CR10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761\u201370.","journal-title":"J Clin Oncol."},{"key":"470_CR11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larran","year":"2012","unstructured":"Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119:1363\u20139.","journal-title":"Blood."},{"issue":"8","key":"470_CR12","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","volume":"19","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama A, Verstovsek S. Molecular pathways: JAK\/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19(8):1933\u201340.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"470_CR13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","volume":"75","author":"GL Plosker","year":"2015","unstructured":"Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015;75(3):297\u2013308.","journal-title":"Drugs."},{"issue":"16","key":"470_CR14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2165\/11209340-000000000-00000","volume":"72","author":"LP Yang","year":"2012","unstructured":"Yang LP, Keating GM. Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012;72(16):2117\u201327.","journal-title":"Drugs."},{"issue":"15","key":"470_CR15","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood."},{"issue":"4","key":"470_CR16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","volume":"120","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513\u201320.","journal-title":"Cancer."},{"key":"470_CR17","unstructured":"European Medicines Agency. Jakavi (ruxolitinib): summary of product characteristics. 2015. http:\/\/ec.europa.eu . Accessed 2 July 2015."},{"key":"470_CR18","unstructured":"Incyte. Jakafi (ruxolitinib) tablets: US prescribing information. 2014. http:\/\/www.jakafi.com . Accessed 3 July 2015."},{"key":"470_CR19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","volume":"51","author":"JG Shi","year":"2011","unstructured":"Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51:1644\u201354.","journal-title":"J Clin Pharmacol."},{"key":"470_CR20","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.110.033787","volume":"38","author":"AD Shilling","year":"2010","unstructured":"Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans. Drug Metab Dispos. 2010;38:2023\u201331.","journal-title":"Drug Metab Dispos."},{"issue":"7","key":"470_CR21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jcph.102","volume":"53","author":"X Chen","year":"2013","unstructured":"Chen X, Williams WV, Sandor V, et al. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol. 2013;53(7):721\u201330.","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"470_CR22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med."},{"key":"470_CR23","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","volume":"113","author":"G Barosi","year":"2009","unstructured":"Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829\u201333.","journal-title":"Blood."},{"key":"470_CR24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961\u20133.","journal-title":"Br J Haematol."},{"key":"470_CR25","unstructured":"Passamonti F, Harrison CN, Pane F, et al. Ruxolitinib vs best available therapy in patients with polycythemia vera treated in the RESPONSE study: a subgroup analysis of hydroxyurea- and non-hydroxyurea-treated patients [abstract]. In: European Hematology Association 20th Congress. 2015."},{"key":"470_CR26","unstructured":"Verstovsek S, Harrison C, Kiladjian JJ, et al. Effect of ruxolitinib on markers of iron deficiency: an analysis of the RESPONSE trial [abstract]. In: European Hematology Association 20th Congress. 2015."},{"key":"470_CR27","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/blood-2014-07-589176","volume":"124","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S, Kiladjian JJ, Mesa R, et al. Ruxolitinib efficacy by hematocrit control in patients with polycythemia vera: an analysis of the RESPONSE trial [abstract no. 3201]. Blood. 2014;124:3201.","journal-title":"Blood"},{"key":"470_CR28","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood.V124.21.3181.3181","volume":"124","author":"JJ Kiladjian","year":"2014","unstructured":"Kiladjian JJ, Vannucchi AM, Griesshammer M, et al. Clinical benefit of ruxolitinib treatment after crossover from best available therapy in patients with polycythemia vera: analysis of the RESPONSE trial [abstract no. 3181]. Blood. 2014;124:3181.","journal-title":"Blood"},{"key":"470_CR29","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib in polycythemia vera: follow-up from the RESPONSE trial [abstract no. 7087]. J Clin Oncol. 2015;33(15 Suppl).","DOI":"10.1200\/jco.2015.33.15_suppl.7087"},{"key":"470_CR30","unstructured":"Griesshammer M, Passamonti F, Durrant S, et al. Ruxolitinib provides consistent hematocrit control in patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea [abstract]. In: European Hematology Association 20th Congress. 2015."},{"key":"470_CR31","unstructured":"Harrison C, Masszi T, Zachee P, et al. Complete hematologic control with ruxolitinib in patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea [abstract]. In: European Hematology Association 20th Congress. 2015."},{"key":"470_CR32","unstructured":"Verstovsek S, Mesa R, Martino B, et al. Safety of ruxolitinib in patients with polycythemia vera: results from the clinical trial program [abstract]. In: European Hematology Association 20th Congress. 2015."},{"key":"470_CR33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755\u201361.","journal-title":"Am J Med."},{"key":"470_CR34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/17474086.2015.1045869","volume":"8","author":"JJ Kiladjian","year":"2015","unstructured":"Kiladjian JJ, Winton EF, Talpaz M, et al. Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol. 2015;8:391\u2013401.","journal-title":"Expert Rev Hematol."},{"key":"470_CR35","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia."},{"key":"470_CR36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/bjc.1981.150","volume":"44","author":"Leukemia and Hematosarcoma Cooperative Group, European Organization for Research on Treatment of Cancer (EORTC)","year":"1981","unstructured":"Leukemia and Hematosarcoma Cooperative Group, European Organization for Research on Treatment of Cancer (EORTC). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer. 1981;44:75\u201380.","journal-title":"Br J Cancer."},{"key":"470_CR37","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","volume":"93","author":"A Alvarez-Larran","year":"2014","unstructured":"Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol. 2014;93:2037\u201343.","journal-title":"Ann Hematol."},{"key":"470_CR38","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047\u201353.","journal-title":"Blood."},{"issue":"5","key":"470_CR39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.blre.2014.06.002","volume":"28","author":"JO Mascarenhas","year":"2014","unstructured":"Mascarenhas JO, Cross NCP, Mesa RA. The future of JAK inhibition in myelofibrosis and beyond. Blood Rev. 2014;28(5):189\u201396.","journal-title":"Blood Rev."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0470-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0470-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T05:56:17Z","timestamp":1599544577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0470-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,11]]},"references-count":39,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["470"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0470-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,11]]}}}